
Join to view full profile
2714 Westwood Ave.Nashville, TN 37212
Phone+1 615-554-7461
Dr. Breyer is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Matthew Breyer is a nephrologist based in Nashville, TN, with an extensive background in nephrology, including expertise in general nephrology, diabetic nephropathy, kidney tubule research, and related biochemical pathways such as cyclooxygenase 2 and prostaglandin E receptors. He completed his medical education at Harvard Medical School, followed by a residency in Internal Medicine at Michael Reese Hospital and Medical Center and a nephrology fellowship at the University of Texas Southwestern Medical Center. Dr. Breyer has held prominent roles, including Chief Scientific Officer Lead Generation at Eli Lilly Corporate Center since 2009 and a position as an attending physician at Richard L. Roudebush Veterans Affairs Medical Center from 2007 to 2018. He was also a professor of Internal Medicine at Vanderbilt University School of Medicine for over two decades. Among his notable publications are those in reputable journals such as Kidney International, Journal of the American Society of Nephrology, and Cell Metabolism. His latest research focuses on molecular categorization of chronic kidney disease and therapeutic responses in diabetic kidney disease.
Education & Training
University of Texas Southwestern Medical CenterFellowship, Nephrology, 1982 - 1985
Michael Reese Hospital and Medical CenterResidency, Internal Medicine, 1979 - 1982
Harvard Medical SchoolClass of 1979
Certifications & Licensure
TN State Medical License 1986 - 2023
Publications & Presentations
PubMed
- 28 citationsUnbiased kidney-centric molecular categorization of chronic kidney disease as a step towards precision medicine.Anna Reznichenko, Viji Nair, Sean Eddy, Damian Fermin, Mark Tomilo
Kidney International. 2024-06-01 - 4 citationsProstacyclin Mitigates Renal Fibrosis by Activating Fibroblast Prostaglandin I 2 Receptor.Jing Li, Yi Guan, Yunyu Xu, Yingxue Cao, Qionghong Xie
Journal of the American Society of Nephrology. 2024-02-01 - 176 citationsMapping the single-cell transcriptomic response of murine diabetic kidney disease to therapies.Haojia Wu, Romer Gonzalez Villalobos, Xiang Yao, Dermot Reilly, Tao Chen
Cell Metabolism. 2022-07-05
Authored Content
- Kidney InternationalApril 2017
Grant Support
- Ppars In CYP450 Dependent Regulation Of Kidney FunctionNational Institute Of Diabetes And Digestive And Kidney Diseases2004–2008
- Cyclooxygenase Stimulated Neovascularization In DiabeticNational Institute Of Diabetes And Digestive And Kidney Diseases2005–2006
- Regulation Of Renal Function By PGE2 And Pgf2a ReceptorsNational Institute Of Diabetes And Digestive And Kidney Diseases2004–2006
- Generating Mouse Mutants With Diabetic NephropathyNational Institute Of Diabetes And Digestive And Kidney Diseases2001–2006
- Regulation Of Na+ Of Absorption On Renal PGE2 ReceptorsNational Institute Of Diabetes And Digestive And Kidney Diseases1999–2003
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:








